Cargando…

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

BACKGROUND: MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy. Here, we report the first case of acquired resistance to immunotherapy in MMR-D pancreatic cancer. CASE PRESENTATION: A 45-year-old woman with unresectable MMR-D pancreatic cancer was initially treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Zishuo Ian, Hellmann, Matthew D., Wolchok, Jedd D., Vyas, Monika, Shia, Jinru, Stadler, Zsofia K., Diaz, Luis A., O’Reilly, Eileen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247688/ https://www.ncbi.nlm.nih.gov/pubmed/30458888 http://dx.doi.org/10.1186/s40425-018-0448-1

Ejemplares similares

Opportunistic infections in patients treated with immunotherapy for cancer
por: Kyi, Chrisann, et al.
Publicado: (2014)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

The delicate balance of melanoma immunotherapy
por: Gyorki, David E, et al.
Publicado: (2013)

The future of cancer immunotherapy: microenvironment-targeting combinations
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2020)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

Combination immunotherapy: a road map
por: Ott, Patrick A., et al.
Publicado: (2017)

DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma
por: Vyas, Monika, et al.
Publicado: (2019)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
por: Zhang, Yuguo, et al.
Publicado: (2022)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Shared cancer neoantigens: Making private matters public
por: Klebanoff, Christopher A., et al.
Publicado: (2018)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Improving health literacy with mumps, measles and rubella (MMR) vaccination: comparison of the readability of MMR patient-facing literature and MMR scientific abstracts
por: Downey, Tina, et al.
Publicado: (2022)

Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Are pediatricians responsible for maintaining high MMR vaccination coverage? Nationwide survey on parental knowledge and attitudes towards MMR vaccine in Serbia
por: Loncarevic, Goranka S., et al.
Publicado: (2023)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Retained Mismatch Repair Protein Expression Occurs in Approximately 6% of Microsatellite Instability-High Cancers and is Associated with Missense Mutations in Mismatch Repair Genes.
por: Hechtman, Jaclyn F., et al.
Publicado: (2019)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer
por: Maletzki, Claudia, et al.
Publicado: (2019)

MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
por: Fraune, Christoph, et al.
Publicado: (2020)

Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study
por: Singh, Ritu R., et al.
Publicado: (2022)

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes
por: Kim, Jin K., et al.
Publicado: (2022)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy
por: Wu, Hui, et al.
Publicado: (2023)

MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama
por: Cai, Liangliang, et al.
Publicado: (2023)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Cross calibration of the Siemens mMR: easily acquired accurate PET phantom measurements, long term stability and reproducibility
por: Keller, Sune H, et al.
Publicado: (2015)

Cross-calibration of the Siemens mMR: easily acquired accurate PET phantom measurements, long-term stability and reproducibility
por: Keller, Sune H., et al.
Publicado: (2016)

Duration of therapy for locally advanced pancreatic cancer: Does it matter?
por: Tuli, Richard, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oc7kdt5t4m15ap52qq14ka4jg6